Alex Biese

A novel cancer vaccine, IO102-IO103, combined with pembrolizumab, showed promising results in improving PFS for advanced melanoma.

The AFSOS-Unicancer QUALIOR study did not meet its primary end point among patients with metastatic cancer.

Patients with ER+/HER2– advanced breast cancer saw positive efficacy and safety data following treatment from the SERENA-1 trial.

Navtemadlin yields improvements in symptom score reductions ad spleen volume reduction among patients with relapsed/refractory myelofibrosis.

Findings from the phase 1/2 CaDAnCe-101 trial showed that promising ORRs in R/R WM and R/R CLL/SLL stemmed from BGB-16673 treatment.

Olverembatinib appears effective in patients with CP-CML without T315I mutations following prior first-line tyrosine kinase inhibitor therapy.

“How do we personalize and improve patient selection for frontline treatment now that patients are living, on average, more than 2 years with this aggressive cancer?” said David H. Aggen, MD, PhD

Superior efficacy outcomes were noted when adagrasib was used to treat patients with KRAS G12C NSCLC and among those with brain metastases.

Neoadjuvant endocrine therapy or paclitaxel with trastuzumab/pertuzumab elicited significant survival in HR-positive, HER2-positive early breast cancer.

Either telehealth or in-person recipes of palliative care did not impact the quality of life outcomes for patients with advanced non–small cell lung cancer.

The overall incidence of bone fractures with prior EBRT to the bone in patients with metastatic castration-resistant prostate cancer remains low.

Patients with hepatocellular carcinoma and Child-Pugh-B liver function appear to have worse overall survival following treatment with regorafenib in the REFINE trial.

Isatuximab plus carfilzomib, lenalidomide, and dexamethasone demonstrates durable responses in patients with newly diagnosed standard- and high-risk multiple myeloma.

Findings from a phase 2a study support further development of a regimen including zanidatamab, palbociclib, and fulvestrant in those with HER2-positive, hormone receptor–positive breast cancer.

Results from the RESTORE study indicate that a cognitive behavioral stress management app improves symptoms of anxiety and depression.